CN105198903A - Pharmaceutical composition for treating acute upper respiratory infection - Google Patents
Pharmaceutical composition for treating acute upper respiratory infection Download PDFInfo
- Publication number
- CN105198903A CN105198903A CN201510755107.1A CN201510755107A CN105198903A CN 105198903 A CN105198903 A CN 105198903A CN 201510755107 A CN201510755107 A CN 201510755107A CN 105198903 A CN105198903 A CN 105198903A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- upper respiratory
- acute upper
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 206010046306 Upper respiratory tract infection Diseases 0.000 title claims abstract description 18
- 206010057190 Respiratory tract infections Diseases 0.000 title abstract 3
- 230000001154 acute effect Effects 0.000 title abstract 3
- 208000020029 respiratory tract infectious disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- -1 microgranules Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
The invention relates to a pharmaceutical composition for treating acute upper respiratory infection. The pharmaceutical composition contains an effective quantity of a compound and a pharmaceutically acceptable vector, wherein the compound has a structure shown in the description. The compound provided by the invention has a significant effect on pathogenic bacteria causing the acute upper respiratory infection, and can be developed into a new clinically-effective pharmaceutical composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of acute upper respiratory tract infection.
Background technology
Acute upper respiratory tract infection is current common clinical, and acute upper respiratory tract infection majority is caused by pathogenic bacterium, finds that in the recent period Klebsiella Pneumoniae ATCC700603 is also one of germ wherein.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of acute upper respiratory tract infection.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of acute upper respiratory tract infection, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of acute upper respiratory tract infection, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment acute upper respiratory tract infection, and this compound has having structure:
Preferably, described infection is caused by Klebsiella Pneumoniae ATCC700603.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition Klebsiella Pneumoniae ATCC700603, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington ' sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogenic bacteria Be very effective causing stomach and intestine, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition Klebsiella Pneumoniae ATCC700603
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination bacterial classification Klebsiella Pneumoniae ATCC700603 purchased from Bei Nuo bio tech ltd, Shanghai.
Nutrient solution
Nutrient agar medium and nutrient broth, purchased from Chen Yu experimental installation company limited of BeiJing ZhongKe.
Test method
Klebsiella Pneumoniae ATCC700603 is inoculated in agar plate nutritive medium plane, evenly gathers during inoculation.
Take target compound 0.01 gram, add 18000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritive medium plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The mean diameter of the bacterial restrain of Klebsiella Pneumoniae ATCC700603 is 13.66mm, and this shows that target compound has the effect of extremely strong vitro inhibition Klebsiella Pneumoniae ATCC700603.
Claims (9)
1. treat a compound for acute upper respiratory tract infection, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for acute upper respiratory tract infection, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of acute upper respiratory tract infection according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of acute upper respiratory tract infection according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of acute upper respiratory tract infection according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of acute upper respiratory tract infection according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment acute upper respiratory tract infection, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infection is caused by Klebsiella Pneumoniae ATCC700603.
9. the purposes of compound in the medicine of preparation vitro inhibition Klebsiella Pneumoniae ATCC700603, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755107.1A CN105198903B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating acute upper respiratory tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755107.1A CN105198903B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating acute upper respiratory tract infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105198903A true CN105198903A (en) | 2015-12-30 |
| CN105198903B CN105198903B (en) | 2016-08-24 |
Family
ID=54946895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510755107.1A Active CN105198903B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating acute upper respiratory tract infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105198903B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105409962A (en) * | 2015-11-09 | 2016-03-23 | 胡昱 | Environment-friendly disinfectant |
| TWI818967B (en) * | 2018-03-22 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5350196A (en) * | 1976-10-15 | 1978-05-08 | Hisamitsu Pharmaceut Co Inc | Novel 4hhpyrido *2*33d**1*3* oxazinee44one derivatives |
| CN103694255A (en) * | 2014-01-09 | 2014-04-02 | 华中师范大学 | Pyridinooxazone-pyridinopyrimidone compounds and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5350196B2 (en) * | 2009-11-26 | 2013-11-27 | アルプス電気株式会社 | Switch device |
-
2015
- 2015-11-09 CN CN201510755107.1A patent/CN105198903B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5350196A (en) * | 1976-10-15 | 1978-05-08 | Hisamitsu Pharmaceut Co Inc | Novel 4hhpyrido *2*33d**1*3* oxazinee44one derivatives |
| CN103694255A (en) * | 2014-01-09 | 2014-04-02 | 华中师范大学 | Pyridinooxazone-pyridinopyrimidone compounds and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 高建宏: "吡啶并噁嗪酮和吡啶并嘧啶酮类化合物的合成与生物活性研究", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105409962A (en) * | 2015-11-09 | 2016-03-23 | 胡昱 | Environment-friendly disinfectant |
| TWI818967B (en) * | 2018-03-22 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105198903B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105503880A (en) | Medicine composition for treating respiratory diseases | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105330610A (en) | Medicine composition for treating gingivitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Dai Xianhui Inventor after: Zhang Xuwei Inventor before: Wei Fang |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160718 Address after: 266109 Chengyang District Qingdao people's Hospital, 600 the Great Wall Road, Chengyang District, Shandong, Qingdao Applicant after: Dai Xianhui Address before: 071003 Hebei Province, Baoding City area Yonghua No. 19 North Street Applicant before: Wei Fang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ma Anshun Inventor before: Dai Xianhui Inventor before: Zhang Xuwei |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170912 Address after: 466224, Henan, Zhoukou province Xiangcheng city government will be the town of Yang Village No. 1 hospital Patentee after: Ma Anshun Address before: 266109 Chengyang District Qingdao people's Hospital, 600 the Great Wall Road, Chengyang District, Shandong, Qingdao Patentee before: Dai Xianhui |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180328 Address after: 226100 Fuxing Road, yuimen Town, Haimen City, Nantong, Jiangsu Province, No. 20 Patentee after: Nantong excellent art design Co., Ltd. Address before: 466224, Henan, Zhoukou province Xiangcheng city government will be the town of Yang Village No. 1 hospital Patentee before: Ma Anshun |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210526 Address after: No. 11, Jinhui Road, Kengzi street, Pingshan District, Shenzhen City, Guangdong Province Patentee after: Jiankangyuan Haibin Pharmaceutical Co.,Ltd. Address before: 226100 Fuxing Road, Yuet Lai Town, Haimen, Nantong, Jiangsu, 20 Patentee before: NANTONG YOUYUAN ART PATTERN DESIGN Co.,Ltd. |